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Abstract
(1) Background: EBV in-situ hybridization and mismatch repair (MMR) protein 
immunohistochemistry identifies two subgroups of gastric cancer (GC) with high 
immunogenicity and likelihood for response to immune checkpoint inhibition. As tumor 
biology may change during the metastatic course which can negatively influence the 
success of therapeutic decisions made on primary tissue, we investigated the 
consistency of GC EBV and MMR status within primary tumors and metastases. (2) 
Patients and Methods: We investigated a cohort of 415 primary resected GC, including 
111 cases with corresponding distant metastases and 297 cases with lymph node 
metastases. Tumors were analyzed by EBV in-situ hybridization and MLH1, PMS2, 
MSH2, and MSH6 immunohistochemistry using tissue microarray technique. (3) Results: 
Primary tumors were grouped EBV-positive MMR-proficient, EBV-negative MMR-
deficient and EBV-negative MMR-proficient. 11/415 (2.7%) of primary tumors were EBV-
positive MMR-proficient whereas 49/415 (11.8%) of tumors were EBV-negative MMR-
deficient. EBV and MMR protein status showed full concordance with that of the primary 
tumors. MMR-deficient tumors were of lower pT-category (p<0.001), had fewer lymph 
node metastases (24/49 (49%) versus 273/361 (75.6%) cases; p<0.001) and a lower rate 
of distant metastases (6/49 (12.2%) versus 105/366 (28.7%) cases; p=0.015). (4) 
Conclusion: We demonstrate a strong correlation of EBV and MMR status between 
primary tumors, lymph node and distant metastases in a large series of primary resected 
GC. The cases showed the expected frequency of EBV-positive MMR-deficient and EBV-
negative MMR-proficient tumors. We conclude that tissue testing for molecular subtyping 
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Introduction 
Gastric cancer (GC) currently is the fifth most common cancer and the third most 
common cause of cancer related death worldwide1,2. Despite advances in therapy 









This article is protected by copyright. All rights reserved
survival rate remains below 40%3. A high rate of resistance towards conventional 
chemotherapeutics and the presence of locally advanced or metastatic disease at the 
time of initial diagnosis appear to be the major factors that contribute to the poor 
outcome4. In the past, GC has been classified according to gross features, the 
predominant histological growth pattern or the cohesiveness of tumor cells. However, 
these classification systems have a limited use for patient management in individual 
cases and correspond only partially to underlying molecular events driving 
tumorigenesis5,6. 
In 2014 and 2015 the Cancer Genome Atlas (TCGA) project and the Asian Cancer 
Research Group (ACRG) provided a molecular classification of GC based on multimodal 
molecular and gene expression analysis of ~300 cases each5,7. Both studies proposed 
four molecular subgroups that were defined by key molecular events provide a basis for 
targeted therapies and correlate to overall survival in case of the ACRG study. The TCGA 
study defines four mutually exclusive subtypes that partially overlap with the ACRG 
subtypes: (1) Epstein-Barr-Virus (EBV)-positive, (2) microsatellite instability (MSI), (3) 
genomically stable (GS) and (4) chromosomal instability (CIN). These molecular 
subtypes can be detected using routine immunohistochemistry and in-situ hybridization 
techniques as demonstrated by previous studies. In particular, identification of EBV-
positive and MSI tumors can be accomplished by using EBER in-situ hybridization and 
Mismatch repair (MMR) protein (MLH1, PMS2, MSH2, and MSH6) 
immunohistochemistry8-10. The concordance rate of MMR expression profiles by 
immunohistochemistry and microsatellite instability testing has been shown to be as high 
as 99% for GC 11. Thus, these techniques may represent a convenient screening tool for 
patient stratification in the clinical setting and to study cohorts of GC that differ from the 
TCGA and ACRG cohorts regarding patient ethnicity, geographic distribution, risk factors 
and tumor stage. 
EBV-positive and MMR-deficient tumors are promising candidates for PD1 (programmed 
cell death protein 1)/PD-L1 (programmed death-ligand 1) based immune checkpoint 
inhibition. This is due to the amplification of the PD-L1 gene in EBV-positive tumors and a 
hypermutated phenotype with a high tumor mutational burden in MMR-deficient 
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in metastatic gastroesophageal malignancies, reliable tissue testing for molecular 
subtyping has major impact on therapeutic decision making. However, data about the 
concordance between the molecular subtype of GC in primary tumors and metastases 
are scarce. We systematically investigated the EBV and MMR status in a well-
characterized western European cohort of 415 primary resected GC with a special focus 




Buffered formalin-fixed paraffin-embedded tumor tissue from patients with gastric 
adenocarcinoma treated at the Department of Surgery, Inselspital Bern, University of 
Bern, Switzerland, was used for this study. We selected those patients from a 
consecutive series between 1993 and 2013 who did not undergo neoadjuvant therapy 
and with enough material and histopathological data and basic clinical information. We 
excluded patients with gastric stump and carcinomas of the gastroesophageal junction. 
First, we included all cases with distant metastasis that where biopsy proven e either 
upon initial diagnosis or during follow-up (n=111). Second, we randomly selected 
additional 304 cases without distant metastasis in order to increase statistical power and 
to include cancers of all stages. The final cohort consisted of 415 primary resected 
chemotherapy-naïve gastric carcinomas, including 111 cases with distant and 297 cases 
with lymph node metastasis. TNM categories and staging were reclassified for all cases 
according to the eighth edition of the UICC TNM classification of malignant tumors. An 
overview of the clinicopathological features of the cohort is illustrated in Table 1. 
Tissue microarray
 A next-generation tissue microarray (ngTMA) containing all cases was constructed as 
described before, with robot assisted digital annotation of the selected slides for placing 
the TMA cores14,15. The TMA consists of three tissue cores (core size 0.6 mm) each of 
the tumor center and the tumor front of the resection specimen as well as corresponding 
lymph node and distant metastases. Full slide sections were obtained for selected cases 
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tumor and corresponding metastases. Approval by the local ethics commission granted 
the use of archival tissue for molecular and immunohistochemical analysis as well as 
TMA construction (University of Bern, Switzerland, No. 200/14). 
Immunohistochemistry and in-situ hybridization
Immunohistochemical staining was performed on an automated immunostainer (Ventana 
BenchMark ULTRA, Roche Diagnostics, Oro Valley, AZ, USA) using the following 
antibodies: MLH1 (clone M1), MSH2 (antibody clone G219-1129), MSH6 (clone SP93) 
and PMS2 (clone A16-4). Pretreatment with Cell Conditioning 1 solution was carried out 
for 64, 40, 64, 92 min and primary antibodies were incubated for 24, 12, 12, min 
respectively. Signal was detected with OptiView Universal DAB Detection Kit and 
Amplification Kit (all antibodies and reagents Ventana, Roche Diagnostics).  EBER in-situ 
hybridization was performed on an automated immunostainer (Bond III, Leica 
Biosystems, Newcastle, UK). A 15 min pretreatment with pyruvate dehydrogenase E1 
(Leica Biosystems) was followed by a 2-h incubation with a ready-to-use EBER probe 
(Bond Ready-to-Use ISH EBER Probe, Leica Biosystems). Immunodetection was 
performed with the Bond Polymer Refine Detection Kit with 3-3′-diaminobenzidine-DAB 
as chromogen (Leica Biosystems). Finally, all samples were counterstained with 
hematoxylin and mounted in Aquatex (Merck, Darmstadt, Germany). Examples of the 
staining are shown in Figure 1. EBER in-situ hybridization was scored as either positive 
or negative according to the presence or absence of a strong intranuclear staining. MMR 
protein expression was scored as retained in the presence of a strong intranuclear 
staining. MMR protein expression was scored based on the presence or absence of 
nuclear staining in tumor cells. Only cores containing non-neoplastic stroma or immune 
cells with strong intranuclear staining for MMR proteins serving as an internal positive 
control were classified as valid for the analysis of MMR protein status. MMR deficiency 
was defined as absence of the expression of MLH1 and PMS2, MSH2 and MSH6, PMS2 
or MSH6. All cases were scored by two independent reviewers (including N.B., B.D. and 
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Statistical analysis was carried out using the IBM SPSS 24.0 Statistics software (IBM, 
Chicago, IL, USA). Correlations between categorical variables were conducted using χ2-
square and Fisher’s exact tests. p values were two-sided and regarded as significant if p 
< 0.05.
Results 
EBV status and MMR protein status in primary tumors: EBER in-situ hybridization as well 
as MLH1, PMS2, MSH2 and MSH6 immunohistochemistry was analyzed in the tissue of 
the primary tumor in all 415 cases. Primary tumors were grouped into three subtypes 
based on EBV and MMR protein status: (1) EBV-positive MMR-proficient (2) EBV-
negative MMR-deficient and (3) EBV-negative MMR-proficient. Only 11/415 (2.7%) of 
primary tumors were EBV-positive MMR-proficient whereas 49/415 (11.8%) of tumors 
were EBV-negative MMR-deficient. All MMR-deficient tumors showed loss of MLH1 
expression with concordant loss of PMS2 expression. A loss of MSH2 and MSH6 
expression was not observed. We did not identify a single tumor that was both EBV-
positive as well as MMR-deficient, a rare phenomenon that has been described 
previously in one of 799 cases of a western GC cohort11. Intratumoral heterogeneity of 
EBV or MMR status between tumor front and tumor center was not observed. 
Representative images of all subtypes are shown in Figure 1. 
Relationship of EBV status and MMR protein status with clinical and histopathological 
parameters: Patients with EBV-positive tumors were more likely to be male (10/11 
(90.9%) versus 247/404 (61.1%) cases; p=0.045), all other relationships with 
clinicopathological parameters were not significant. Patients with MMR-deficient tumors 
were older (median age 75 years (45-92 years) versus median age 69 years (31-93 
years); p<0.001), tumors were of lower pT-category (p<0.001), had fewer lymph node 
metastases (24/49 (49%) versus 273/361 (75.6%) cases; p<0.001) and a lower rate of 
distant metastases (6/49 (12.2%) versus 105/366 (28.7%) cases; p=0.015). In addition, 
MMR-deficient tumors were of lower histological grade (p=0.025), predominantly of 
intestinal type morphology (41/49 (83.7%) versus 171/366 (46.7%) cases; p<0.001) and 
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EBV status and MMR protein status along the metastatic course: MLH1 
immunohistochemistry was analyzed in 269/297 (90.6%) lymph node and 98/111 (88.3%) 
distant metastases. EBER in-situ hybridization was analyzed in 284/297 (95.6%) lymph 
node and 103/111 (92.8%) distant metastases. In all investigated metastatic cases EBV 
and MMR protein status showed complete concordance with that of the primary tumors. 
Representative images of primary tumors and their metastases are shown in Figure 2.
Discussion
The molecular classification of GC into four subtypes as proposed by TCGA allows the 
stratification of GC patients into different prognostic and predictive groups5,7. Among the 
four subtypes, MSI and EBV-positive tumors have gained attention, as they are 
candidates for PD1/PD-L1 based immune checkpoint inhibition, which has become a 
promising therapeutic option in advanced GC10,12. We therefore analyzed EBV and MMR 
protein status in the primary tumors and corresponding metastases in a large western 
cohort of primary resected GC. The frequency of EBV-positive and MMR-deficient tumors 
in our cohort is slightly lower in comparison to GC cohorts of previous publications, where 
EBV-positive tumors occurred in a range between 4-14% and MMR-deficient tumors 
between 8-26%5,7-11,16. We hypothesize that the observed differences of EBV frequency 
are mainly due to different patient populations under study, and reflect the known 
geographical variance of EBV positivity; with both ethnicity and lifestyle as well as 
environmental risk factors and co-infections as contributing factors17. We exclude 
intratumoral heterogeneity as a potential source of declaring a case as false negative, as 
all EBV-positive cases showed uniform positivity in all TMA tissue cores where tumoral 
tissue was present. In addition, we selectively analyzed full slide sections of EBV-positive 
cases that also demonstrated a uniform positivity. Our data supports the previous 
observation that MSI in GC is due to loss of MLH1 expression in the vast majority of 
cases, as none of our MMR deficient cases showed a loss of MSH2, MS6H or isolated 
loss of PMS2 expression18. In addition, this is to our knowledge the first study that 
systematically investigated the EBV and MMR protein status in corresponding lymph 
node and distant metastasis. Our comparative analysis of lymph node and distant 
metastases showed full concordance of EBV and MMR protein status along the 
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First, the evaluation of EBV or MMR protein status for immunotherapy eligibility testing 
either on tissue of the primary tumor or the metastasis is sufficient and that there is no 
need to reevaluate metachrone metastases. Second, the primary tumor and its 
metastases likely have a similar putative response towards immune checkpoint inhibition, 
as the molecular key events that predict response are preserved along the metastatic 
course.
One major limitation of our study is the low number of EBV-positive GCs. All EBV-positive 
GCs show concordant EBV-positive metastases, but we cannot rule out that EBV 
expression might potentially be lost during the metastatic course of disease in a larger 
study population. The second major limitation of our study is the lack of a long-term follow 
up and thus missing overall survival data. However, the detailed pathological parameters 
available show a prognostic association of patients with MMR-deficient tumors and a 
more favorable course of disease, with a lower frequency of lymph node and distant 
metastases, lower histological grade and tumor stage, which is in line with previous 
studies 5,16,19,20. Since the basic pathological characterization of our cohort is comparable 
to data from literature and our focus was set on the correlation of EBV and MMR status in 
primary tumors and metastases we consider the lack of clinical follow up as an 
acceptable weakness. The third major limitation of our study is the retrospective study 
design. Our cohort consist of primary resected tumors encompassing cases from a 
historical pre-neoadjuvant therapy era, as the initial diagnosis for the vast majority of our 
cases was before the publication of the MAGIC trial in 200621. However, this allows us to 
study molecular alterations without the biological interference of preoperative 
chemotherapy. Most of the tumors would have now been treated by neoadjuvant therapy, 
and the clinical course may be influenced by the local and systemic response to this 
treatment as well12,22. Moreover, several multimodal treatment concepts exist which also 
may have different impact on the clinical course of patients with different molecular 
subtypes of GC. 
In conclusion, we demonstrate a strong correlation of EBV and MMR status between 
primary tumors, lymph node and distant metastases, using in situ hybridization and 
immunohistochemistry in a large series of GC. In addition, we speculate that the 
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metastases remains unchanged irrespective of adjuvant therapy, although we lack 
detailed clinical data regarding the administration of postoperative chemotherapy. The 
investigated cases showed the expected frequency of EBV-positive MMR-deficient and 
EBV-negative MMR-proficient tumors. We conclude that tissue testing for molecular 
subtyping for potential therapeutic decision-making can be reliably performed on both 
primary tumors and metastases in GC. 
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Table 1
Clinicopathological characteristics of the patient cohort in relationship to EBV status and 
mismatch repair protein status
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Figure 1: Representative images of TMA cores of primary tumors stained with an 
antibody directed against MLH1 and with an EBER in-situ hybridization probe.
Figure 2: Preservation of EBV status and Mismatch Repair Protein status along the 
metastatic course of gastric cancer A: Representative images of an EBV-positive MMR-
proficient primary tumor and the corresponding distant metastasis. B:  Representative 
images of an EBV-negative MMR-deficient primary tumor and the corresponding lymph 
node metastasis. A
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